{"ok":true,"entity":{"id":"incyte","name":"Incyte Corporation","entityType":"company","officialName":"Incyte Corporation","canonicalName":"Incyte Corporation","displayName":"Incyte Corporation","category":"血液・腫瘍・炎症性自己免疫疾患領域のバイオ医薬品企業","shortDescription":"Incyte Corporationはデラウェア州ウィルミントンに事業所を置く米国のバイオ医薬品企業で、血液、腫瘍、炎症性・自己免疫疾患の3領域を中核としています。2026年7月28日発表の第2四半期は総売上高が約16億7,400万ドルで、2026年7月6日にはVega Therapeutics買収の完了を発表しました（2026年10月時点）。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.incyte.com/","updatedAt":"2026-10-20T07:08:03.177Z","secondaryClusters":[],"alias":["Incyte","インサイト・コーポレーション"],"searchKeywords":["インサイト","Incyte","Jakafi","ジャカビ","Opzelura","VGA039","血液疾患","骨髄線維症","バイオ医薬品","INCY"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}